A novel anti-LILRB4 chimeric antigen receptor (CAR) T cell therapy recently demonstrated potent elimination of human LILRB4+ AML cells in preclinical models with no toxicity on normal CD34+ hematopoietic cells (307). This evidence concerns the gene LILRB4 and acute myeloid leukemia.